Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial r...
Is there any indication of changes in the company's burn rate or operating expenses that might affect future profitability?
What is the expected impact of the recent clinical updates on the probability of success for its lead candidates?
Did the business update mention any changes to the company's strategic focus or pipeline diversification that could affect long‑term growth prospects?
25 days ago